or search for allinseo plug in" Diabetes » Advice on Health and Body Matters

Archive for the ‘Obesity and related illnesses’ Category

Barley as a Diabetic Treatment

Thursday, October 29th, 2009

Diabetes is often associated with obesity. Apart from taking medication, there are other natural approaches which one can consider by consuming certain kinds of food. Your browser may not support display of this image.

High in fibre, barley is also a kidney cleanser. Better yet, regular intake of it helps prevent heart disease. BARLEY water was always a regular drink when we were still living at home. Whenever we had to go for a medical exam that included a urine test, my mum would make us drink barley water a day before it to make sure we got a positive result!

My mother was a wise woman. I later found out from an Australian
naturopath that barley is known to be a kidney cleanser.

Barley is good for your intestinal health too. Try to eat the barley
grains you find in your drink or sweet broth with fu chook (beancurd skin) and ginkgo nuts.

It’s high in fibre which feeds the friendly bacteria in the colon and
helps speed up the transit of fecal matter in it. In this way it helps
prevent haemorrhoids and colon cancer.

The propionic acid and beta glucan from barley’s insoluble fibre also help lower cholesterol and prevent the formation of gallstones.

Eating barley regularly is a preventive step against heart disease as,
besides the fibre content, it is also high in niacin, a B vitamin good for
lowering cholesterol.

Diabetics should eat more barley as the fibre will prevent blood sugar
levels from rising too high. It also provides relief from constipation or
diarrhoea for those suffering from Irritable Bowel Syndrome.

Barley is rich in selenium which prevents cancer and relieves symptoms of asthma and arthritis. It is a good source of manganese, copper and phosphorous.

Malt sugar comes from sprouted barley which, when fermented, is an ingredient in beer and other alcoholic beverages.

Your browser may not support display of this image. Barley, whose Latin name is hordeum vulgare, has been cultivated for more than 10,000 years.

Since ancient times, barley has been used for healing purposes and has
been known to the Chinese, Egyptians, Greeks and Romans. Athletes in
Greece and Rome in those days were known to eat barley bread to give them strength.

Besides the usual things we do with barley, I enjoy having it in a western soup. The larger pearl barley is used and I love the sticky bite of it.

Here’s a recipe for barley soup:

Barley soup with roasted garlic

1 cup pearl barley
5 cloves whole garlic, roasted
2 litres chicken stock, steeped from 1 chicken breast simmered in three litres water
2 tbsps vegetable oil
2 large onions, diced
2 carrots, diced
2 stalks celery, diced
150g turkey ham, cut up
1 tsp ground white pepper
1 tsps sea salt or to taste
1 tbsp chopped parsley

Method
1. Wash barley and soak it in a bowl of water for three hours. Drain.

2. Heat oil in pan and fry onions. Add carrots and celery, then the barley and fry for three minutes.

3. Add chicken stock, pepper and roasted garlic and simmer over low heat for at least an hour, or until barley is soft.

4. Add salt to taste and serve the soup garnished with chopped parsley.

Technorati Tags:

FDA Issues Update to Safety Review on Cholesterol-Lowering Drugs

Tuesday, October 20th, 2009

For those taking drugs that lower cholesterol, the article below is useful…

The U.S. Food and Drug Administration today reaffirmed its position that elevated amounts of low-density lipoprotein (LDL), or “bad cholesterol,” are a risk factor for cardiovascular diseases such as heart attack, stroke and sudden death and that lowering LDL cholesterol reduces the risk of these diseases.

FDA’s comments are contained in an update to its Jan. 25, 2008, Early Communication describing the agency’s review of data from ENHANCE, a clinical trial comparing Zocor (simvastatin), a drug that lowers cholesterol production in the liver, to Vytorin, a drug that combines Zocor with another drug, Zetia (ezemtimibe), which inhibits cholesterol absorption.

Preliminary results from ENHANCE (Effect of Combination Ezetimibe and High-Dose Simvastatin vs. Simvastatin Alone on the Atherosclerotic Process in Patients with Heterozygous Familial Hypercholesterolemia) had indicated there was no significant difference between Vytorin and Zocor-treated patients in the thickness of the walls of the blood vessels of the neck (the carotid arteries) although there was greater lowering of the amount of LDL cholesterol in patients with Vytorin compared to Zocor.

Measuring the thickness of the carotid arteries via ultrasound imaging is considered a biomarker of risk for cardiovascular disease.

FDA has now completed its review of the final clinical trial report of ENHANCE. After two years of treatment, there was no significant difference in carotid artery thickness between Vytorin patients and Zocor patients. However, the levels of LDL cholesterol, decreased by 56% in the Vytorin group and decreased by 39% in the Zocor group.
The results from ENHANCE do not change FDA’s position on the benefits of lowering LDL cholesterol. Based on currently available data, patients should not stop taking Vytorin or other cholesterol-lowering drugs and should talk to their doctor or other health care professional if they have any questions about Vytorin, Zetia or the ENHANCE trial.

FDA’s Early Communications are disclosures that the agency has begun evaluating new data about a drug and is considering regulatory action, but has yet to reach a conclusion.

The update is posted on FDA’s Web site.

RSS Feed for FDA News Releases

Technorati Tags:

New Drug for Gout sufferers

Thursday, September 10th, 2009

Here’s an article from the FDA about a new drug for Gout…a common disease in Obese people…..

The U.S. Food and Drug Administration has approved Colcrys to treat acute flairs in patients with gout, a recurrent and painful form of arthritis, and patients with familial Mediterranean fever (FMF), an inherited inflammatory disorder. The medication’s active ingredient is colchicine, a complex compound derived from the dried seeds of a plant known as the autumn crocus or meadow saffron (Colchicum autumnale).

Colchicine has been used by healthcare practitioners for many years to treat gout but had not been approved by the FDA. The FDA has an initiative underway to bring unapproved, marketed products like colchicine under its regulatory framework. This initiative promotes the goal of assuring that all marketed drugs meet modern standards for safety, effectiveness, quality and labeling.

Physicians historically have given colchicine hourly for acute gout flares until the flare subsided or they had to stop treatment because the patient began experiencing gastrointestinal problems. A dosing study required as part of FDA approval demonstrated that one dose initially and a single additional dose after one hour was just as effective as continued hourly dosing for acute gout flares, but much less toxic. As a result, the drug is being approved for acute gout flares with the lower recommended dosing regimen.

The FDA is alerting healthcare professionals to this new dosing regimen and also warning about the potential for severe drug interactions when patients take colchicine.

The medicinal value of using colchicum was first identified in the first century A.D. and its use for treating acute gout dates back to 1810. Physicians have prescribed the medication since then. Although single-ingredient colchicine has not been approved by the FDA until now, a combination product containing colchicine and an agent that increased the excretion of uric acid in the urine was approved by the FDA in 1939.

FMF is the most common of the hereditary periodic fever syndromes and is characterized by recurrent episodes of fever, arthritis and painful inflammation of the lining layers of the lungs and abdomen.  Though rare in the United States, it is more common in Mediterranean countries. Physicians have prescribed colchicine for FMF for many years based on studies showing that it reduced the frequency of attacks but use of colchicine for FMF had never been approved. With this approval, Colcrys becomes the first drug approved to treat FMF.

Colcrys is manufactured by Mutual Pharmaceutical Company, Inc., Philadelphia.

More Information:

RSS Feed for FDA News Releases

Technorati Tags:

FDA Approves New Drug Treatment for Type 2 Diabetes

Tuesday, September 1st, 2009

The article below gives alternative treatment for Type-2 Diabetics:

The U.S. Food and Drug Administration today approved Onglyza (saxagliptin), a once-daily tablet to treat Type 2 diabetes in adults. The medication is intended to be used with diet and exercise to control high blood sugar levels.

The hormone insulin keeps blood sugar (glucose) levels within a narrow range in people who don’t have diabetes. People with Type 2 diabetes are either resistant to insulin or do not produce enough insulin to maintain normal blood sugar levels.

Onglyza is in a class of drugs known as dipeptidyl peptidase-4 (DPP-4) inhibitors which stimulate the pancreas to make more insulin after eating a meal.

“Keeping blood sugar levels in adequate control is essential to the good health of the 24 million people in the United States with Type 2 diabetes,” said Mary Parks, M.D., director of the Division of Metabolism and Endocrinology Products in the FDA’s Center for Drug Evaluation and Research. “High blood sugar levels can cause blurry vision and excessive urination and eventually result in such serious conditions as kidney and eye disease.”

The most common side effects observed with Onglyza are upper respiratory tract infection, urinary tract infection, and headache. Other side effects include allergic-like reactions such as rash and hives.

Approval of Onglyza was primarily based on the results of eight clinical trials. The application seeking FDA approval was submitted before December 2008 when the agency recommended that manufacturers of new diabetes drugs carefully design and evaluate their clinical trials for cardiovascular safety. Although Onglyza was not associated with an increased risk for cardiovascular events in patients who were mainly at low risk for these events, the FDA is requiring a postmarket study that will specifically evaluate cardiovascular safety in a higher risk population.

Onglyza is manufactured by Bristol-Myers Squibb Co. of Princeton, N.J., and marketed by Bristol-Myers and AstraZeneca Pharmaceuticals LP, of Wilmington, Del.

RSS Feed for FDA News Releases

Technorati Tags: , ,

Insulin patch for Diabetics

Friday, August 21st, 2009

For Diabetics who need to enure the pain and discipline required in the use or injection pens, the following article is nice to know…read more below…

Medingo’s insulin patch approved; shares rocket

By Nick Taylor, 30-Jul-2009

Medingo’s insulin dispensing patch has been approved by the US Food and Drug Administration (FDA), sending shares in its parent company soaring to a 12 month high.

The company claims the patch, called Solo, is the smallest, thinnest, lightest and most discrete insulin pump without cumbersome tubing. Solo consists of two components: an insulin dispensing patch and a remote control.

Using the remote patients can customise the patch’s output to match their insulin needs. Gaining approval for the patch is regarded as a major milestone by Arie Mientkavich, chairman of Medingo.

Solo is set to be showcased at the American Association of Diabetes Educators Meeting, which takes place in Atlanta, US in August 2009. Mientkavich said the Medingo is “currently considering alternatives for its go-to-market strategy and the timing of the product launch”.

Release of the news sent the share price of Medingo’s parent company, Elron Electronics Industries, up by 56.4 per cent. The rise demonstrates investors’ belief in the opportunities that exist for products that deliver insulin in a more convenient way.

Sustained growth

Approval of Medingo’s Solo patch coincided with the release of a report into the transdermal drug delivery market by Greystone Associates.

The report predicts a period of sustained growth for the transdermal drug delivery market and highlights some areas other than diabetes where the technology is effective.

In particular the report believes that transdermal patches will be useful for the elderly, who tend to be less able to self-medicate than other patients groups. The aging population means that this will provide an increasingly large market.

To achieve a sustainable growth model, which the report says has so far eluded the transdermal delivery sector, Greystone predicts companies will pursue two strategies.

Firstly companies will achieve growth by increasing market penetration in key transdermal therapeutic segments by refining product strategies. A second source of growth will come from companies seeking to extend product lifecycles in the face of patent expiration.

The report believes that growth can be achieved by expanding into new therapeutic areas and working with companies that market patent protected products.

  • A possible replacement of Rosiglitazone and Pioglitazone for Type II Diabetes?
    Findings from the Phase II SYNCHRONY study show that aleglitazar, a treatment for Type 2 diabetes, could be safe and effective and thus will be entered into Phase III trials. The data, already published online and forthcoming in The Lancet, were presented at the recent American Diabetes Association meeting in New Orleans, La. Aleglitazar is in [...]
  • New Hope for Type II Diabetics
    GlaxoSmithKline in February announced initiation and dosing of the first patient of the Phase III clinical trial programme to evaluate the efficacy, safety, and tolerability of the investigational GLP-1 (Glucagon-like peptide 1) agonist Syncria® (albiglutide) in men and women with type 2 diabetes. The Phase III program will include more than 4,000 patients […]
  • New Studies on Weight Loss Drug - promising results
    I know that many chronic obese people rely on Weight loss drugs to control their weight. No doubt despite the side effects, some people have really tried everything to natuarally lose weight, but to no avail. With a doctor’s advice, they resort to medication. These naturally come with side effects, and sometimes are not even [...]
  • Warning about Venom HYPERDRIVE 3.0 supplements
    FDA Warns Consumers Against Dietary Supplement Containing Undeclared Drug Product poses safety risk The U.S. Food and Drug Administration is warning consumers not to take Venom HYPERDRIVE 3.0, a product sold as a dietary supplement and containing sibutramine. Sibutramine, a controlled substance with risks for abuse or addiction, is a potent drug [...]
Pages
H1N1 Fraudulent Products update







Tai Chi WeightLoss